EsteéoconteúdodoClinicalKey

Quer mais respostas?

Inscreva-se hoje para um teste gratuito do ClinicalKey! Seu primeiro passo para obter as respostas certas quando você precisa delas. O ClinicalKey é uma solução de conhecimento clínico projetada para ajudar profissionais de saúde e estudantes a encontrar as respostas certas, fornecendo conhecimento aprofundado e baseado em evidências - tudo em um mesmo recurso.

Summary
Basic Information
Diagnosis
Workup
History
Differential Diagnosis
Treatment
Special Considerations
Follow-up

Nov.16.2022

Postural Orthostatic Tachycardia Syndrome

Summary

Key Points

The cardinal feature of postural orthostatic tachycardia syndrome is excessive orthostatic tachycardia
Postural orthostatic tachycardia syndrome is a chronic multisystem disorder with many different potential manifestations
The typical patient with postural orthostatic tachycardia syndrome is a female of childbearing age
Postural orthostatic tachycardia syndrome is associated with poor quality of life and significant functional disability
Postural orthostatic tachycardia syndrome patients often have neurocognitive complaints (brain fog), but do not seem to have a higher rate of anxiety or depression than the general population
Patients with postural orthostatic tachycardia syndrome often feel faint, and 20% to 30% will experience syncope
While postural orthostatic tachycardia syndrome cannot be cured, it can be treated
Treatment begins with nonpharmacologic approaches to increase blood volume (augmented dietary salt and water), aerobic exercise training (non-upright at least initially), and lower-body compression garments
Many patients with postural orthostatic tachycardia syndrome will require medications in addition to the nonpharmacologic approaches. However, there are no FDA-approved pharmacologic treatments for postural orthostatic tachycardia syndrome

Basic Information

Postural orthostatic tachycardia syndrome is characterized by orthostatic tachycardia in the absence of orthostatic hypotension and additional multisystem manifestations
Common symptoms include palpitations, lightheadedness, extreme fatigue, exercise intolerance, headache, and mental clouding

Terminology

Outdated terms for postural orthostatic tachycardia syndrome include Da Costa syndrome,¹ soldier’s heart, mitral valve prolapse syndrome,² neurocirculatory asthenia, orthostatic tachycardia, and orthostatic intolerance³
Orthostatic hypotension: sustained decrease in systolic blood pressure 20 mm Hg and higher or diastolic blood pressure 10 mm Hg and higher within 3 minutes of standing or on head-up tilt test⁴
Initial orthostatic hypotension: transient drop in systolic blood pressure of 40 mm Hg or more, or diastolic blood pressure 20 mm Hg or more, which occurs within 15 seconds of standing, with blood pressure recovery within 45 seconds of standing^5,6
Peripheral acrocyanosis (postural orthostatic tachycardia syndrome feet): dependent cyanosis characterized by dark red-blue discoloration of the feet
Orthostatic intolerance: a constellation of symptoms that include frequent, recurrent, or persistent lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, exercise intolerance, and fatigue on standing. These symptoms can occur with or without orthostatic tachycardia or syncope. Individuals with orthostatic intolerance have 1 or more of these symptoms associated with reduced ability to maintain upright posture

Epidemiology

Postural orthostatic tachycardia syndrome primarily affects females of childbearing age
- The female:male ratio is more than 5:1⁷
  - The reason for the strong female predominance in postural orthostatic tachycardia syndrome is not known. However, females also have a higher prevalence of orthostatic intolerance compared to males⁸ and a higher prevalence of conditions that often co-occur with postural orthostatic tachycardia syndrome (eg, autoimmune disease, irritable bowel syndrome)
- A large online patient-community survey⁷ of self-reported postural orthostatic tachycardia syndrome patients found that most initially present with symptoms in adolescence and early adulthood
  - The most common age of symptom onset was 14 years with a median age of 17 years, and 50% of patients had symptom onset before 18 years of age⁷
- The natural history of postural orthostatic tachycardia syndrome is not clear, but it does not appear to increase the risk of mortality⁹

Quality of Life in Postural Orthostatic Tachycardia Syndrome

Patients with postural orthostatic tachycardia syndrome are often young females of childbearing age whose work productivity and quality of life are negatively affected¹⁰
Functional impairment in patients with postural orthostatic tachycardia syndrome has been reported to be similar to that in chronic obstructive pulmonary disease and congestive heart failure¹¹
Over 25% of postural orthostatic tachycardia syndrome patients are unable to work as a result of their disability¹¹
Postural orthostatic tachycardia syndrome patients describe poorer sleep quality, more daytime sleepiness, less sleep efficiency,¹² greater fatigue, and substandard quality of life compared to healthy subjects¹⁰

Postural Orthostatic Tachycardia Syndrome Triggers

Patient-reported survey data show that in approximately 40% of postural orthostatic tachycardia syndrome patients, symptoms began following acute stressors (eg, presumed viral illness [most common], pregnancy, major surgery)
Symptoms develop more insidiously in the remainder of patients⁷
Some patients have developed postural orthostatic tachycardia syndrome following infection with the SARS-CoV2 virus.¹³ This has been termed long-COVID postural orthostatic tachycardia syndrome. The exact mechanisms are uncertain, but they are presumed to be a sequelae of the immune response to the virus
A small observational study found that about 80% of female patients report an exacerbation of symptoms around menstruation¹⁴

Etiology and Risk Factors

Etiology

There is likely a multitude of underlying pathophysiologic mechanisms across the spectrum of postural orthostatic tachycardia syndrome patients
- Standing tachycardia is a final common pathway of many pathophysiologic processes
- Postural orthostatic tachycardia syndrome should be viewed as a clinical syndrome rather than a single disease
- Many disorders with orthostatic tachycardia have been described
An overarching schema of different putative mechanisms that could lead to a postural orthostatic tachycardia syndrome presentation is shown in Figure 1

Coexisting Conditions

Postural orthostatic tachycardia syndrome patients often suffer from coexisting disorders that may contribute to the overall limitations of their functional status and health-related quality of life
Table 1 lists the most common self-reported coexisting conditions by postural orthostatic tachycardia syndrome patients in a large patient survey⁷

Table 1. Associated disorders commonly coexisting with postural orthostatic tachycardia syndrome.
Comorbid condition	Prevalence
Chronic migraine/severe headache	40%
Hypermobile Ehlers-Danlos syndrome and hypermobile spectrum	25%
Chronic fatigue syndrome/myalgic encephalomyelitis	21%
Fibromyalgia	20%
Autoimmune disorders	16%
Mast cell activation disorder	9%

Chronic Migraines/Headaches

Headaches are reported in approximately 90% of postural orthostatic tachycardia syndrome patients, and the most common diagnosis is migraine¹⁵
Focus treatments on traditional headache management, as the directed treatment of the heart rate and blood pressure in postural orthostatic tachycardia syndrome may not decrease their frequency or severity
A minority of patients will have headaches that are worse with upright posture. In these cases, consider the diagnosis of spontaneous intracranial hypotension¹⁶

Ehlers-Danlos Syndrome and Joint Hypermobility Disorders

Ehlers-Danlos syndrome is a family of heterogeneous disorders associated with inherited abnormalities of collagen
Key clinical problems include skin hyperextensibility, joint hypermobility, and fragile connective tissues¹⁷
Patients with Ehlers-Danlos syndrome, and most commonly those with the hypermobile form of Ehlers-Danlos syndrome (formerly type III), frequently have autonomic symptoms that are also common in patients with postural orthostatic tachycardia syndrome, including lightheadedness, palpitations, chest pains, presyncope, and syncope
- These symptoms can be triggered by exercise, warm or hot environment, and standing^18,19
- Similar to postural orthostatic tachycardia syndrome patients, patients with Ehlers-Danlos syndrome have disturbed sympathetic cardiovascular control on autonomic testing²⁰
- More recent studies of autonomic symptoms/function and quality of life in patients with the hypermobile form of Ehlers-Danlos syndrome confirm a high prevalence of postural orthostatic tachycardia syndrome–like orthostatic symptoms and orthostatic intolerance in these patients
- Wallman et al.¹⁷ found that about 18% of the postural orthostatic tachycardia syndrome patients in their sample met criteria for Ehlers-Danlos syndrome (versus 0.02% prevalence in the general population and 4% prevalence in their non–postural orthostatic tachycardia syndrome autonomic clinic patients)
- The reasons for the relationship between postural orthostatic tachycardia syndrome and the hypermobile form of Ehlers-Danlos syndrome are unknown
- Connective tissue abnormalities in Ehlers-Danlos syndrome could lead to vascular laxity and predispose patients to orthostatic blood pooling in the lower extremities and orthostatic intolerance, although this association has not been proven²⁰
- Alternatively, these patients might have a peripheral neuropathy that could contribute to autonomic impairment¹⁹

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Chronic fatigue syndrome/myalgic encephalomyelitis is characterized by persistent or relapsing unexplained fatigue, postexertional malaise, unrefreshing sleep, cognitive impairment, and orthostatic intolerance of at least 6 months duration²¹
Like postural orthostatic tachycardia syndrome, chronic fatigue syndrome/myalgic encephalomyelitis is more commonly diagnosed in females
Patients with postural orthostatic tachycardia syndrome have a high prevalence of chronic fatigue (48%-77%) and of chronic fatigue syndrome/myalgic encephalomyelitis (17%-23%)²²

Autoimmune Disorders

Postural orthostatic tachycardia syndrome patients have a higher than average prevalence of autoimmune disorders^7,23 including celiac disease,²⁴ Hashimoto thyroiditis,²⁵ Sjögren syndrome,²⁶ and systemic lupus erythematosus²⁷
If a specific autoimmune disorder is found, target therapy toward treatment of that specific autoimmune disorder

Mast Cell Activation Syndrome

Some postural orthostatic tachycardia syndrome patients have symptoms suggestive of abnormal mast cell activation⁷
These postural orthostatic tachycardia syndrome patients commonly report episodes of flushing, urticaria, dyspnea, headache, excessive diuresis, and gastrointestinal symptoms (eg, diarrhea, nausea, vomiting)
To confirm the diagnosis, assess for elevated urine methylhistamine (a histamine metabolite) or urinary 11-β-prostaglandin F₂ (a prostaglandin D₂ metabolite), acute elevations in serum tryptase, or elevation in the levels of other mast cell mediators²⁸

Diagnosis

Approach to Diagnosis

Diagnostic Criteria

Postural orthostatic tachycardia syndrome is a clinical syndrome that requires both excessive orthostatic tachycardia and chronic symptoms of orthostatic intolerance (Figure 2)^4,9,29
- Orthostatic tachycardia is not, by itself, sufficient to make the diagnosis of postural orthostatic tachycardia syndrome
A diagnosis of postural orthostatic tachycardia syndrome requires the chronic presence of symptoms of orthostatic intolerance (for at least 3 months) accompanied by a heart rate increase of at least 30 beats per minute within 10 minutes of assuming an upright posture in patients 20 years or older
- Normal physiologic orthostatic tachycardia is higher in children and adolescents and decreases with increasing age, so the threshold for excessive orthostatic tachycardia is a heart rate increase of at least 40 beats per minute for those patients aged 12 to 19 years
- There is not a defined heart rate criterion in North America for patients aged younger than 12 years
Excessive orthostatic tachycardia should occur in the absence of orthostatic hypotension (a fall in systolic blood pressure 20/10 mm Hg or more)
The diagnosis requires the absence of prolonged bed rest, medications that impair autonomic regulation (eg, vasodilators, diuretics, antidepressants, anxiolytic agents), or any other disorders that might cause tachycardia (eg, dehydration, anemia, Addison disease, hyperthyroidism) (Table 2)

Table 2. Criteria for the postural orthostatic tachycardia syndrome.

Sustained heart rate increase of 30 beats per minute or higher from supine to standing or head-up tilt within 10 minutes in patients aged 20 years or older In patients aged 12 to 19 years, the heart rate increase must be 40 beats per minute or higher to be considered excessive
The excessive orthostatic tachycardia must occur in the absence of significant orthostatic hypotension (blood pressure fall 20/10 mm Hg or more)
Symptoms get worse with standing and better with recumbence
Symptoms are chronic, lasting 3 or more months
Absence of other overt cause of orthostatic symptoms or tachycardia (eg, active bleeding, acute dehydration, prolonged bedrest, hyperthyroidism, Addison disease, medications)

Caveats With the Postural Orthostatic Tachycardia Syndrome Hemodynamic Criteria

While the heart rate criterion must occur in the absence of orthostatic hypotension, the transient orthostatic hypotension seen with initial orthostatic hypotension does not preclude the diagnosis of postural orthostatic tachycardia syndrome if orthostatic tachycardia is sustained
Patients with postural orthostatic tachycardia syndrome may occasionally have orthostatic hypotension (especially when hypovolemic)
Orthostatic tachycardia can vary from day to day, and throughout a day,³⁰ and depends on whether a stand test or a head-up tilt test³¹ was used for assessment
- Heart rate criterion does not need to be met on every assessment to maintain the diagnosis of postural orthostatic tachycardia syndrome
Assess heart rate frequently (5-10 times), or continuously over the 10-minute upright assessment
Excessive orthostatic tachycardia must be sustained, meaning that the heart rate above threshold should be seen on at least 2 readings at least 1 minute apart (and not a transient increase in heart rate that rapidly falls below the heart rate threshold)²⁹
- Typically, once the heart rate exceeds the threshold with upright posture, it remains that way for the upright duration
- In contrast, the heart rate in a disorder such as initial orthostatic hypotension can increase initially and then recover over a few minutes
Some people have a very low resting heart rate that rises to normal values on standing. Even if these reach the threshold of 30 or more beats per minute,⁹ it does not necessarily indicate postural orthostatic tachycardia syndrome. Adjustment should be made for the low resting heart rate in the assessment
The Canadian Cardiovascular Society proposed a floor resting heart rate of 60 beats per minute for the purpose of the orthostatic tachycardia assessment²⁹
- For example, if an adult had a resting heart rate of 50 beats per minute, an upright heart rate of 81 beats per minute would not be adequate to meet the postural orthostatic tachycardia syndrome heart rate criterion. Rather, they would need to have an upright heart rate 90 beats per minute or higher (based on a floor heart rate of 60 beats per minute + 30 beats per minute = 90 beats per minute)

Workup

Include a complete history, physical examination, and measurement of orthostatic vital signs at initial evaluation
Order routine blood tests:
- CBC
- Electrolyte levels (Na⁺, K⁺, and Cl⁻)
- Renal function (creatinine and urea)
- TSH³²
Consider a ferritin level (iron stores) and a morning cortisol level to exclude Addison disease²⁹
Obtain an ECG on all patients
Refer to a specialist (eg, cardiologist, neurologist) for additional diagnostic workup if necessary:
- Additional laboratory studies
- 24-hour Holter monitoring
- Autonomic testing
- Echocardiography
- Tilt-table testing
- Exercise stress tests²⁹

History

Evaluate for common symptoms (see Table 2):
- Palpitations
- Shortness of breath
- Tremulousness
- Chest discomfort
- Headache
- Lightheadedness
- Perceived mental clouding (brain fog)
- Fatigue²²
- Nausea
- Poor sleep¹⁰
Presyncope is common in these patients; however only 20% to 30% of patients lose consciousness and experience frank syncope
Evaluate for exercise intolerance and ability to complete activities of daily living
Evaluate for positional changes in symptoms
- While many symptoms may be worse with upright posture, some symptoms are not necessarily positional (eg, lightheadedness, sleep disturbances, fatigue)
Table 3 lists some common symptoms of orthostatic intolerance that are seen in postural orthostatic tachycardia syndrome patients

Table 3. Symptoms associated with postural orthostatic tachycardia syndrome.

Common orthostatic intolerance symptoms
– Light headedness– Palpitation (heart racing)– Dyspnea– Tremulousness– Atypical chest discomfort
Other commonly reported symptoms not necessarily associated with particular postures
– Sleep disturbances– Headaches– Chronic fatigue– Chronic pain– Exercise intolerance and deconditioning– Perceived cognitive impairment (brain fog)– Peripheral acrocyanosis (postural orthostatic tachycardia syndrome feet)– Frequent nausea– Mild diarrhea/constipation/bloating/unspecific abdominal pain
Debilitating noncardiovascular symptoms seen in some postural orthostatic tachycardia syndrome patients
– Intractable headaches– Severe chronic pain– Joint hypermobility– Gastric emptying problems (too fast or too slow) with intractable nausea and sometimes vomiting– Severe constipation and/or diarrhea– Neurogenic bladder/incontinence/urinary retention– Significant flushing/anaphylaxis symptoms– Severe food intolerances– Paresthesia and numbness

Physical Examination

Physical examination findings are often normal in a patient with postural orthostatic tachycardia syndrome, aside from orthostatic vital signs
Assess orthostatic vital signs to evaluate whether excessive tachycardia develops on standing from a supine position
- Heart rate and blood pressure must be measured after lying supine for 3 to 5 minutes and then again after standing at 1 minute, 3 minutes, 5 minutes, 8 minutes, and 10 minutes
- There should be a sustained heart rate increase of 30 beats per minute or higher in adults (and 40 beats per minute or higher in patients aged 12-19 years) and the systolic blood pressure should not fall by more than 20 mm Hg
  - In many cases, systolic blood pressure will actually increase with standing
- Excessive tachycardia must be sustained by the end of the 10 minutes or more (not briefly go up and then come back down while still standing)²⁹
A murmur of mitral valve prolapse may be present on cardiac auscultation, but significant mitral regurgitation is unusual
Targeted neurologic examination for signs of a peripheral neuropathy if suggestive symptoms are present
Assess for joint hypermobility syndrome or Ehlers-Danlos syndrome, if suggested by the history
Evaluate for peripheral acrocyanosis (postural orthostatic tachycardia syndrome feet)
- Dependent acrocyanosis occurs in 40% to 50% of patients with postural orthostatic tachycardia syndrome (Figure 3), characterized by dark red-blue discoloration from the feet to above the knees (in some cases), and is cool to the touch

Laboratory Tests

In the initial evaluation for selected patients with postural orthostatic tachycardia syndrome, potential secondary causes of orthostatic tachycardia may be identified with a basic set of routine blood tests, including:
- CBC
- Electrolyte levels (Na+, K+, and Cl−)
- Renal function (creatinine and urea)
- Ferritin level
- TSH level
- A morning cortisol measurement to assess for adrenal failure²⁹
- If there is a suggestion of an autoimmune disorder in the medical history, then targeted further testing would be appropriate
Further testing under guidance of specialty physicians may include:
- Assessment of plasma norepinephrine levels in both a supine and standing position (10 minutes in each position before blood sampling from an indwelling IV catheter)
  - The supine norepinephrine level is often high-normal in patients with postural orthostatic tachycardia syndrome, while the upright norepinephrine level is often elevated (more than 600 pg/mL), a reflection of the exaggerated neural sympathetic tone that is present in these patients while upright³³
- In evaluating for mast cell activation disorder for patients with episodic flushing coexistent with tachycardia, consider ordering the following tests as close to the episode as possible:
  - 4-hour urinary methylhistamine or prostaglandin F_2α
  - Serum tryptase levels
- Assessment of sodium intake through measurement of 24-hour urine for sodium and creatinine levels
  - Although there is slight day-to-day variability, the amount of sodium excreted in the urine is close to the amount of sodium ingested
- There are some data suggesting that postural orthostatic tachycardia syndrome patients with low urinary sodium excretion are most responsive to increases in dietary sodium³⁴

Diagnostic Procedures

ECG

Postural orthostatic tachycardia syndrome patients should have only sinus tachycardia
Order an ECG routinely to rule out the presence of an accessory bypass tract or any abnormalities of cardiac conduction^9,29
- A Holter monitor⁹ may be prescribed to evaluate for presence of a re-entrant dysrhythmia, especially if the patient gives a history of paroxysmal tachycardia with a sudden onset and sudden offset
If there is concern about underlying structural heart disease or accessory pathways, conduct further cardiac testing under the supervision of a cardiologist
- Postural orthostatic tachycardia syndrome patients should not have structural heart disease
  - If structural heart disease cannot be ruled out clinically, then echocardiography might be warranted

Other Diagnostic Tools

Further diagnostic testing is generally managed by specialty physicians or centers that focus on autonomic or neurologic disorders

Autonomic Testing

Head-up Tilt Table Test
- Head-up tilt table test is a common test for autonomic functioning as a standardized method to assess the response to upright posture³⁵
- The patient is positioned supine on a tilt table; following baseline measurements of blood pressure and heart rate, the patient is inclined to a 70° head-up angle
- Blood pressure and heart rate are ideally measured continuously with a beat-to-beat blood pressure monitor
- A similar threshold is used to diagnose orthostatic tachycardia (an increase of more than 30 beats per minute in adults) with the tilt test as with the active stand test
Autonomic Cardiovascular Reflex Testing
- Test results of cardiovascular autonomic nervous system function typically show intact or exaggerated autonomic reflex responses
- Patients with postural orthostatic tachycardia syndrome often have preserved cardiovagal function as reflected by sinus arrhythmia ratio in response to deep breathing
- Patients with postural orthostatic tachycardia syndrome often have a vigorous pressor response to the Valsalva maneuver, with an exaggerated blood pressure recovery before release and exaggerated blood pressure overshoot after release, although this response can vary
  - The vigor of the heart rate and blood pressure responses may be useful to guide initial therapies, according to clinical experience
    - Patients with a blunted blood pressure recovery may benefit more from a pressor medication (eg, midodrine)
    - Patients with a vigorous blood pressure recovery may be more hyperadrenergic and may respond to central sympatholytic medications

Blood Volume Assessment

The blood volume is low in many patients with postural orthostatic tachycardia syndrome³⁶
Blood volume can be objectively assessed with nuclear medicine tests to directly measure either the plasma volume or the red cell volume (or mass)
This knowledge may help to focus the treatment plan

Neuropsychological Evaluation

Patients with postural orthostatic tachycardia syndrome may present with symptoms of depression, anxiety, and memory deficits
Consider referring for formal neuropsychological testing to evaluate for deficits in cognition, memory, or executive functioning if patients have such complaints
- Raj et al. demonstrated that postural orthostatic tachycardia syndrome patients did not have a higher rate of anxiety disorders, major depressive disorder, or substance abuse than the general population³⁷
- Arnold et al.³⁸ performed a comprehensive neuropsychological evaluation of 28 postural orthostatic tachycardia syndrome patients and found impaired executive functioning and deficits in selective attention and cognitive processing, but no difference in memory function, compared to healthy controls

Differential Diagnosis

Table 4. Differential diagnosis: postural orthostatic tachycardia syndrome.
Condition	Description	Differentiated by
Orthostatic hypotension	Sustained decrease in systolic blood pressure 20 mm Hg or more, or in diastolic blood pressure 10 mm Hg or more, within 3 minutes of standing or on head-up tilt test⁴	Orthostatic hypertension patients are often older, and they may have signs of a neurodegenerative disease; POTS patients have tachycardia in the absence of hypotension
Initial orthostatic hypotension	Transient drop in systolic blood pressure of 40 mm Hg or more, or in diastolic blood pressure 20 mm Hg or more, that occurs within 15 seconds of standing, with blood pressure recovery within 45 seconds of standing; there can be a reflex tachycardia^5,6	POTS symptoms do not get better with continued standing
Vasovagal syncope	A form of reflex (or neurally mediated) fainting preceded by sustained upright posture (standing or sitting with the legs down)Can be triggered by pain, emotional distress, severe anxietyUsually characterized by hypotensionHeart rate can be low, normal, or elevated	POTS patients often feel faint, but only a minority have true syncope
Inappropriate sinus tachycardia	Characterized by symptomatic resting sinus tachycardia without an obvious other cause.³⁹ The criteria require a supine daytime resting heart rate 100 beats per minute or more, or a 24-hour mean heart rate 90 beats per minute or more.⁹ There may be excessive orthostatic tachycardia, although it is not required for diagnosis	POTS associated with tachycardia upright, but often normal heart rate while supine
Pheochromocytoma	Paroxysms of hyperadrenergic symptoms caused by elevated epinephrine and norepinephrine secretion from an adrenal tumor. Patients with either POTS or pheochromocytoma can have very high heart rate while upright, but patients with pheochromocytoma are more likely than POTS patients to have symptoms while lying down	Supine plasma norepinephrine (and normetanephrine) levels are usually higher in patients with pheochromocytoma
PSWT²⁹	If a patient has typical symptoms of orthostatic intolerance, but does not exhibit excessive orthostatic tachycardia, they are said to have PSWT	No excessive orthostatic tachycardia
Postural tachycardia owing to an underlying medical condition or PTOC	Patients meet diagnostic criteria for POTS but have acute or chronic medical conditions or a medication that could exacerbate orthostatic tachycardia. If the contributary condition resolves, they can be reassessed to see if they meet POTS criteria	Comorbid condition, potentially treatable, that could underlie or exacerbate orthostatic tachycardia

Treatment

Nondrug and Supportive Care

Focus initial treatment efforts on identifying and treating any reversible causes
Withdraw potentially contributory medications, especially vasodilators, diuretics, and drugs that inhibit the norepinephrine transporter, such as:
- Atomoxetine
- Duloxetine
- Reboxetine
- Stimulants
- Venlafaxine
Treatment modalities include increased water and salt intake, use of compression stockings, exercise, and possible use of IV saline infusion
Optimize treatment for any chronic disease that is present
Focus patient education on avoidance of aggravating factors (eg, dehydration, extreme heat)

Table 5. Nonpharmacologic treatment modalities for postural orthostatic tachycardia syndrome.
Therapy	Dosage	Comments
Water	3 L/day	Can be a challenge in patients with gastroparesis
Increasedietary salt	10-12 g NaCl/day(2 teaspoons)	To help to retain more fluid; can cause nausea (especially on an empty stomach)
Waist-high compression garments/abdominal binder	30-40 mm Hg counter-pressure; abdominal binder or waist-highTriathlon tights	Works to enhance venous return when upright; abdominal compression is more important than leg compression
Exercise	30 minutes x 4 days per week; primarily aerobic reconditioning	Non-upright (eg, rowing, recumbent cycle); often feels worse before improvement
Acute IV saline	1 L normal saline over 1-3 hours IV	Effective at acute heart rate control; inconvenient; medical setting needed

Increase Dietary Salt and Water Intake

Both the Heart Rhythm Society⁹ and the Canadian Cardiovascular Society²⁹ recommend that postural orthostatic tachycardia syndrome patients ingest a significant amount of water and sodium. However, there are no data on the long-term efficacy of this approach
3L of water per day is recommended and 10g NaCl (approximately 2 teaspoons of salt per day)
Recent data suggest that high dietary sodium (compared to low dietary sodium) increases plasma volume, reduces standing plasma norepinephrine, and reduces standing tachycardia in postural orthostatic tachycardia syndrome patients⁴⁰
Dietary salt intake does not have a major effect on serum sodium levels (because it leads to a plasma volume expansion, which normalizes the serum concentration)

Waist-High Compression Stockings

Use of high-waist compression stockings targeting abdomen and thighs, or an abdominal binder, can provide hemodynamic support for patients with postural orthostatic tachycardia syndrome and is recommended by subject matter experts²⁹
In a proof-of-concept study, external compression from the abdomen to the legs decreased the drop in stroke volume and reduced the heart rate with head-up tilt⁴¹

Exercise Training Program

Exercise training has been repeatedly shown to improve symptoms in patients with postural orthostatic tachycardia syndrome^42,43,44
One study found that 3 months of exercise training decreased orthostatic tachycardia, decreased symptom burden, and improved quality of life⁴⁵
Non-upright exercises are strongly recommended:
- Rowing machines
- Recumbent cycles
- Swimming
Exercise should be performed regularly (every other day; 4 per week) for 30 minutes duration each session⁴⁶
Counsel patients that they may feel worse initially and may require a graded approach to exercise therapy (for up to 6 weeks); however, sustained exercise often leads to symptom improvements

Acute Blood Volume Expansion

IV saline provides some patients with symptomatic relief and control of heart rate⁴⁷
While IV saline can be used in an acute or emergent setting, it is not a practical plan for long-term management. The primary concern is long-term IV access and the complications of central catheters
Both the Heart Rhythm Society⁹ and Canadian Cardiovascular Society²⁹ have made regular and repeated saline infusions a class III recommendation (recommendation against routine use)

Drug Therapy

Pharmacologic Treatment of Postural Orthostatic Tachycardia Syndrome

There are no FDA-approved medications for the treatment of postural orthostatic tachycardia syndrome; thus, all medications that are used for this disorder are off-label
No pharmacologic agents have been tested in randomized clinical trials lasting longer than 1 month. A summary of pharmacologic approaches to treating postural orthostatic tachycardia syndrome is shown in Table 6⁴⁸

Table 6. Pharmacologic treatments for postural orthostatic tachycardia syndrome.
Therapy	Dosage	Comments
Propranolol	10-20 mg PO 4 times a day	Nonselective β-blocker; use in low doses; can worsen fatigue or hypotension
Ivabradine	2.5-7.5 mg PO 2 times a day	I_funny (I_f) channel blocker; can cause visual disturbance or fatigue; can be expensive
Midodrine	2.5-15 mg PO 3 times a day	α-1 adrenergic receptor agonist; can cause piloerection, worsen headaches, or rarely urinary retention
Pyridostigmine	30-60 mg PO 3 times a day	Peripheral acetylcholinesterase inhibitor; can increase colonic motility with cramping and diarrhea; can worsen bladder irritability (but may be helpful in patients with constipation)
Methyldopa	125-250 mg PO 2 times a day	False neurotransmitter; decreases central sympathetic nervous system traffic; can cause hypotension and drowsiness
Clonidine	0.05-0.2 mg PO 2 to 3 times a day,or0.1-0.3 mg/24-hours transdermal patch every 7 days	Agonist of presynaptic α-2 receptor; decreases central sympathetic nervous system traffic; can worsen mental clouding, fatigue, or drowsiness. Abrupt cessation can lead to rebound hypertension
Fludrocortisone	0.05-0.2 mg POdaily (can split dose)	Blood volume expansion; can cause hypokalemia (check K⁺); worsen headaches, hypertension, osteoporosis, edema
DDAVP	0.1-0.2 mg POdaily or nightly	Blood volume expansion; can cause hyponatremia (check Na⁺); can worsen headache or edema
Modafinil	100-200 mg PO up to 2 times a day	Mild stimulant; may reduce mental clouding; mild increase in heart rate

Propranolol

Propranolol can be a useful first line medication in many patients who are symptomatic from the tachycardia that occurs with standing
It may be particularly useful in those with very high standing heart rates
Experts in the field recommend 10 to 20 mg up to 4 times a day⁴⁹
Goal of treatment is to improve excessive tachycardia but not normalize it completely
- Complete normalization of heart rate will usually cause intolerable symptoms
Higher doses cause excessive fatigue and are typically not tolerated
- While small doses of propranolol (20 mg) can lead to significant symptomatic improvement in postural orthostatic tachycardia syndrome patients, higher doses (80 mg) can aggravate symptoms⁴⁹

Ivabradine

Ivabradine⁵⁰ has recently been approved by the FDA for treatment of heart failure. It is a I_funny (I_f)_{channel blocker that lowers the heart rate, with little effect on blood pressure}
One nonrandomized case series found that 60% of patients with postural orthostatic tachycardia syndrome reported relief on this medication⁵¹
Recently, a small randomized trial of ivabradine was performed in 22 patients with hyperadrenergic postural orthostatic tachycardia syndrome.⁵² Ivabradine improved symptoms more than placebo in this cohort, providing the first high-quality evidence for ivabradine in this group
The starting dose is often 5 mg twice daily with up- or down-titration to 7.5 mg or 2.5 mg per dose²⁹
It is fairly well tolerated, although some patients describe visual alterations or fatigue
Ivabradine is associated with fetal toxicity; thus, females with reproductive potential must use effective contraception

Midodrine

Midodrine is a prodrug that is converted to desglymidodrine, a selective α1-adrenergic agonist, and acts as both a vasoconstrictor and venoconstrictor
Midodrine may be particularly helpful in patients with very soft blood pressures, where a decrease in peripheral venoconstriction or vasoconstriction may be present
Midodrine has a half-life of about 4 hours
- Peak concentrations are reached in 1 to 2 hours⁵³
Typical dose is 2.5 to 15 mg every 4 hours, up to 3 times a day²⁹
Common adverse effects include piloerection, scalp tingling, urinary retention, and headache

Pyridostigmine

Pyridostigmine is an acetylcholinesterase inhibitor, which increases levels of acetylcholine at postganglionic muscarinic and nicotinic receptors, leading to a net increase in parasympathetic tone
It can decrease the heart rate in response to standing and reduce symptom burden in patients with postural orthostatic tachycardia syndrome⁵⁴
When used in clinic outpatients, the majority of postural orthostatic tachycardia syndrome patients reported improvement, but approximately 20% of patients had to stop medication owing to adverse effects of diarrhea and abdominal cramping^29,55
Typical dose is 30 to 60 mg 3 times a day

Central Sympatholytic Medications

Central sympatholytic medications are often useful and well tolerated in postural orthostatic tachycardia syndrome patients with severe hyperadrenergic features, but may not be as well tolerated in hyperadrenergic symptoms at doses of 125 mg to 250 mg PO twice a day⁵⁶
- Starting dose is recommended to be 125 mg at bedtime and with slow increase by 125 mg per increment
- Avoid use for patients with active liver disease
Clonidine is an α-2 agonist that acts centrally to decrease sympathetic nervous system tone
- Clonidine, at doses of 0.05 mg to 0.2 mg PO 2 to 3 times daily, can stabilize heart rate and blood pressure in patients with grossly excessive sympathetic nervous system tone
- Clonidine may also be administered via transdermal patch, which may be advantageous owing to continuous medication release, at doses of 0.1 to 0.3 mg/24 hours applied every 7 days
- Clonidine has a short half-life, and it can cause drowsiness and fatigue and worsen the mental clouding of some postural orthostatic tachycardia syndrome patients. Abrupt discontinuation of clonidine may precipitate withdrawal symptoms

Fludrocortisone

Fludrocortisone (an aldosterone analogue) can be added for patients with hypovolemia who do not respond to augmentation of salt and water intake
Through enhanced sodium retention, it theoretically expands the plasma volume, although there is a paucity of data regarding the exact mechanisms of action
Adverse effects can include hypokalemia, hypomagnesemia, worsening migraine headaches, acne, and fluid retention with edema, although it is usually well tolerated in most individuals
Doses of up to 0.2 mg/day have a low incidence of hypokalemia and are unlikely to suppress the hypothalamic-pituitary-adrenal axis⁵⁷

Desmopressin

Oral vasopressin is a volume-expanding agent that may be helpful for short-term use by causing the kidney to retain free water but not sodium
There is evidence that oral vasopressin 0.2 mg PO and 500 mL water can acutely lower orthostatic tachycardia and improve symptoms⁵⁸
Check serum sodium at least weekly to monitor for potential adverse effects, including edema, headache, and hyponatremia
Excessive use is strongly discouraged

Modafinil

Modafinil is a stimulant (with unclear mechanism) that some postural orthostatic tachycardia syndrome patients have used improve alertness at a dose of 100 mg twice daily
Modafinil can increase sympathetic activation,⁵⁹ but it seems to increase heart rate only modestly in postural orthostatic tachycardia syndrome patients⁶⁰
Caution is advised as it may aggravate the orthostatic tachycardia⁸

Treatment Procedures

Procedural treatments for postural orthostatic tachycardia syndrome are all considered class III (do not routinely recommend) by both the Heart Rhythm Society and the Canadian Cardiovascular Society^9,29
Radiofrequency modification of the sinus node can lower or eliminate the tachycardia, but they often do not improve symptoms
- This is an area of ongoing procedural research

Persistent or Recurrent Disease

Postural orthostatic tachycardia syndrome is a chronic condition that can be treated but not typically cured
The clinical course can wax and wane with improvements followed by setbacks due to various stressors

Admission Criteria

The management of postural orthostatic tachycardia syndrome is a long-term endeavor that is usually best managed in an outpatient setting
Admission is driven by associated clinical problems that justify it, and not because of a diagnosis of postural orthostatic tachycardia syndrome

Special Considerations

POTS Plus

Patients with postural orthostatic tachycardia syndrome may have a combination of orthostatic and/or nonorthostatic symptoms
- Patients may have variable improvement of orthostatic symptoms and nonorthostatic symptoms during their postural orthostatic tachycardia syndrome treatment
- In some cases, persistent severe nonorthostatic symptoms may reflect another underlying problem
- The terms POTS plus can be used to reflect the added complexity from these symptoms or significant coexisting conditions

Follow-up

Monitoring

Specialists with experience with autonomic dysfunction should follow postural orthostatic tachycardia syndrome patients regularly on an outpatient basis, as treatments will sometimes need adjustment
Monitor orthostatic vital signs and other associated symptoms for improvement

Prognosis

Robust data are lacking regarding the long-term prognosis in postural orthostatic tachycardia syndrome
Very few adult patients are cured, but many experience improvement in their symptoms and daily function with treatment
There is a suggestion that children with postural orthostatic tachycardia syndrome may have significant improvement or abatement of symptoms once they reach adulthood, but the data are quite poor

Referral

Postural orthostatic tachycardia syndrome patients have a multisystem illness and often require the expertise of a myriad of specialists
The primary postural orthostatic tachycardia syndrome specialists often have initial training in neurology, cardiology, or internal medicine, but their interest and expertise in the management of postural orthostatic tachycardia syndrome is more important than their primary Medical Board certification
Refer to a cardiologist if there is concern about structural heart disease or arrhythmia
Refer to a neurologist if patient presents with neurologic deficits or for management of complicated headaches or migraine
Refer to a gastroenterologist if there are significant gastrointestinal motility issues
Refer to an allergist or immunologist for signs of mast cell activation syndrome, multiple allergies, or signs such as dermographism
Refer to a geneticist if there is concern about coexistent Ehlers-Danlos syndrome
Consider a physiotherapist to help with the exercise program or joint stabilization

Johnston JH. Mitral valve prolapse: the facts. J R Army Med Corps. 1989;135:76-78.

2671358

https://doi.org/10.1136/jramc-135-02-06Gaffney FA et al. Abnormal cardiovascular regulation in the mitral valve prolapse syndrome. Am J Cardiol. 1983;52:316-320.

6869279

https://doi.org/10.1016/0002-9149(83)90130-3Miller JW et al. Vascular responsiveness to norepinephrine in sympathicotonic orthostatic intolerance. J Lab Clin Med. 1990;115:549-558.

2160509

Freeman R et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69-72.

21431947

https://doi.org/10.1007/s10286-011-0119-5Harms MPM et al. Systemic and cerebral circulatory adjustment within the first 60 s after active standing: an integrative physiological view. Auton Neurosci. 2021;231:102756.

33385733

https://doi.org/10.1016/j.autneu.2020.102756van Wijnen VK et al. Initial orthostatic hypotension in teenagers and young adults. Clin Auton Res. 2016;26:441-449.

27637670

https://doi.org/10.1007/s10286-016-0382-6Shaw BH et al. The face of postural tachycardia syndrome: insights from a large cross-sectional online community-based survey. J Intern Med. 2019;286.

30861229

https://doi.org/10.1111/joim.12895Fu Q et al. Effects of gender and hypovolemia on sympathetic neural responses to orthostatic stress. Am J Physiol Regul Integr Comp Physiol. 2005;289:R109-R116.

15761188

https://doi.org/10.1152/ajpregu.00013.2005Sheldon RS et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41-e63.

25980576

https://doi.org/10.1016/j.hrthm.2015.03.029Bagai K et al. Sleep disturbances and diminished quality of life in postural tachycardia syndrome. J Clin Sleep Med. 2011;7:204-210.

21509337

Benrud-Larson LM et al. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc. 2002;77:531-537.

12059122

https://doi.org/10.4065/77.6.531Bagai K et al. Estimation of sleep disturbances using wrist actigraphy in patients with postural tachycardia syndrome. Auton Neurosci. 2013;177:260-265.

23538032

https://doi.org/10.1016/j.autneu.2013.02.021Johansson M et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep. 2021;3(4):573-580.

33723532

https://doi.org/10.1016/j.jaccas.2021.01.009Peggs KJ et al. Gynecologic disorders and menstrual cycle lightheadedness in postural tachycardia syndrome. Int J Gynecol Obstet. 2012;118:242-246.

22721633

https://doi.org/10.1016/j.ijgo.2012.04.014Cortez MM et al. Synergistic but separable sensory changes in postural tachycardia syndrome and chronic migraine. Clin Auton Res. 2021;31:263-271.

33174112

https://doi.org/10.1007/s10286-020-00740-yD'Amico D et al. Headache in spontaneous intracranial hypotension: an overview with indications for differential diagnosis in the clinical practice. Neurol Sci. 2020;41:423-427.

33034803

https://doi.org/10.1007/s10072-020-04642-9Wallman D et al. Ehlers–Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurol Sci. 2014;340:99-102.

24685354

https://doi.org/10.1016/j.jns.2014.03.002De Wandele I et al. Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls. Semin Arthritis Rheum. 2014;44:353-361.

24968706

https://doi.org/10.1016/j.semarthrit.2014.05.013De Wandele I et al. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. Semin Arthritis Rheum. 2014;44:93-100.

24507822

https://doi.org/10.1016/j.semarthrit.2013.12.006Gazit Y et al. Dysautonomia in the joint hypermobility syndrome. Am J Med. 2003;115:33-40.

12867232

https://doi.org/10.1016/s0002-9343(03)00235-3CDC. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. CDC IOM 2015 Diagnostic Criteria. Reviewed April 27, 2021. Accessed February 9, 2022.https://www.cdc.gov/me-cfs/healthcare-providers/diagnosis/iom-2015-diagnostic-criteria.htmlOkamoto LE et al. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. Clin Sci (Lond). 2012;122:183-192.

21906029

https://doi.org/10.1042/CS20110200Vernino S et al. Autoimmunity in postural orthostatic tachycardia syndrome: current understanding. Auton Neurosci. 2018;215:78-82.

29909990

https://doi.org/10.1016/j.autneu.2018.04.005Penny HA et al. Is there a relationship between gluten sensitivity and postural tachycardia syndrome? Eur J Gastroenterol Hepatol. 2016;28:1383-1387.

27606948

https://doi.org/10.1097/MEG.0000000000000740Blitshteyn S. Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). Lupus. 2015;24:1364-1369.

26038344

https://doi.org/10.1177/0961203315587566Goodman BP. Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci. 2018;215:12-19.

29705015

https://doi.org/10.1016/j.autneu.2018.04.004Tang S et al. Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia. Rheumatology. 2004;43:609-614.

14983104

https://doi.org/10.1093/rheumatology/keh132Shibao C et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385-390.

15710782

https://doi.org/10.1161/01.HYP.0000158259.68614.40Raj SR et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020;36:357-372.

32145864

https://doi.org/10.1016/j.cjca.2019.12.024Brewster JA et al. Diurnal variability in orthostatic tachycardia: implications for the postural tachycardia syndrome. Clin Sci (Lond). 2012;122:25-31.

21751966

https://doi.org/10.1042/CS20110077Plash WB et al. Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics. Clin Sci (Lond). 2013;124:109-114.

22931296

https://doi.org/10.1042/CS20120276Vernino S et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton Neurosci. 2021;235:102828.

34144933

https://doi.org/10.1016/j.autneu.2021.102828Garland EM et al. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 2007;69:790-798.

17709712

https://doi.org/10.1212/01.wnl.0000267663.05398.40Zhang Q et al. Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. J Pediatr. 2012;161:281-284.

22424949

https://doi.org/10.1016/j.jpeds.2012.01.054Low PA et al. Postural tachycardia syndrome (POTS). Neurology. 1995;45:S19-S25.

7746369

Satish RR et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005;111:1574-1582.

15781744

https://doi.org/10.1161/01.CIR.0000160356.97313.5DRaj V et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. J Neurol Neurosurg Psychiatry. 2009;80:339-344.

18977825

https://doi.org/10.1136/jnnp.2008.144360Arnold AC et al. Cognitive dysfunction in postural tachycardia syndrome. Clin Sci (Lond). 2015;128:39-45.

25001527

https://doi.org/10.1042/CS20140251Olshansky B et al. Inappropriate sinus tachycardia. Europace. 2019;21:194-207.

29931244

https://doi.org/10.1093/europace/euy128Garland EM et al. Effect of high dietary sodium intake in patients with postural tachycardia syndrome. J Am Coll Cardiol. 2021;77:2174-2184.

33926653

https://doi.org/10.1016/j.jacc.2021.03.005Bourne KM et al. Compression garment reduces orthostatic tachycardia and symptoms in patients with postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77:285-296.

33478652

https://doi.org/10.1016/j.jacc.2020.11.040Fu Qet al. Exercise and non-pharmacological treatment of POTS. Auton Neurosci. 2018;215:20-27.

30001836

https://doi.org/10.1016/j.autneu.2018.07.001George SA et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm. 2016;13:943-950.

26690066

https://doi.org/10.1016/j.hrthm.2015.12.012Gibbons CH et al. Cardiovascular exercise as a treatment of postural orthostatic tachycardia syndrome: a pragmatic treatment trial. Heart Rhythm. 2021.

33482385

https://doi.org/10.1016/j.hrthm.2021.01.017Fu Q et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2010;55:2858-2868.

20579544

https://doi.org/10.1016/j.jacc.2010.02.043Raj SR. Row, row, row your way to treating postural tachycardia syndrome. Heart Rhythm. 2016;13:951-952.

26738945

https://doi.org/10.1016/j.hrthm.2015.12.039Jacob G et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation. 1997;96:575-580.

9244228

https://doi.org/10.1161/01.cir.96.2.575Miller AJ et al. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci. 2018;215:28-36.

29753556

https://doi.org/10.1016/j.autneu.2018.04.008Raj SR et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009;120:725-734.

19687359

https://doi.org/10.1161/CIRCULATIONAHA.108.846501Corlanor (ivabradine tablets)[package insert]. Amgen Inc.; 2015 Apr.McDonald C et al. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427-430.

21062792

https://doi.org/10.1093/europace/euq390Taub PR et al. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77:861-871.

33602468

https://doi.org/10.1016/j.jacc.2020.12.029ProAmatine (midodrine hydrochloride tablets)[package insert]. Shire US Inc.; 2017 Jan.Raj SR et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111:2734-2740.

15911704

https://doi.org/10.1161/CIRCULATIONAHA.104.497594Kanjwal K et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34(6):750-755.

21410722

https://doi.org/10.1111/j.1540-8159.2011.03047.xJacob G et al. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci. 1999;317:88-101.

10037112

https://doi.org/10.1097/00000441-199902000-00003Sheldon R et al. Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2016;68(1):1-9.

27364043

https://doi.org/10.1016/j.jacc.2016.04.030Coffin ST et al. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm. 2012;9:1484-1490.

22561596

https://doi.org/10.1016/j.hrthm.2012.05.002Taneja I et al. Modafinil elicits sympathomedullary activation. Hypertension. 2005;45:612-618.

15753235

https://doi.org/10.1161/01.HYP.0000158267.66763.63Kpaeyeh J et al. Hemodynamic profiles and tolerability of modafinil in the treatment of postural tachycardia syndrome: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 34:738-741.

25222185

https://doi.org/10.1097/JCP.0000000000000221